

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
September 26, 2018**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Urovant Sciences Ltd.

File No. 333-226169 - CF#36470

Urovant Sciences Ltd. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on July 13, 2018.

Based on representations by Urovant Sciences Ltd. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1	through June 28, 2021
Exhibit 10.2	through June 28, 2021
Exhibit 10.3	through June 28, 2021
Exhibit 10.4	through June 28, 2021
Exhibit 10.5	through June 28, 2021
Exhibit 10.10	through June 28, 2021
Exhibit 10.11	through August 30, 2021

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary